


E PIPAMPERONE/CN
 SET EXPAND CONTINUOUS
 L1 1 S E3
 E ESCITALOPRAM/CN

 L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2011 ACS on STN
 RN 128196-01-0 REGISTRY
 ED Entered STN: 13 Jul 1990
 CN 5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, (1S)- (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, (S)-
 OTHER NAMES:
 CN (+)-(S)-1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
 CN (+)-(S)-Citalopram
 CN (+)-Citalopram
 CN (S)-Citalopram
 CN Escitalopram
 CN S-(+)-Citalopram
 CN Seroplex
 FS STEREOSEARCH
 MF C20 H21 F N2 O
 CI COM
 SR CA
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, EMBASE, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PS, REAXYSFILE*, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



L2 1 S E15

 FILE 'CAPLUS' ENTERED AT 09:37:00 ON 11 JUL 2011
 L3 23 S L1 AND L2
 L4 1 S L3 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)
 L5 7 S US 20070078162/PN
 E 5-HT REUPTAKE INHIBITORS/IT
 E 5-HT REUPTAKE INHIBITORS/CT
 L6 4398 S E39
 L7 14 S L1 AND L6
 L8 7 S L7 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)

L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN

AB The present invention relates to methods of treating of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperaesthesia-dissociative phenomena-...) using compds. and compns. of compds. having D4 and/or 5-HT2A antagonistic, partial agonistic or inverse agonistic activity. The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compds. having D4 antagonistic, partial agonistic or inverse agonistic activity and/or (ii) compds. having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and/or (iii) any known medicinal compound and compns. of said compds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biol. compound or in two different chemical and/or biol. compds. The combination can also be used to augment the therapeutic effect of or to provide a faster onset of the therapeutic effect of a selective serotonin re-uptake inhibitor, a norepinephrine re-uptake inhibitor, an NK1 antagonist, or a musculoskeletal disease-treating COX-2 inhibitor. Pharmaceutical compns. are also claimed.

ACCESSION NUMBER: 2005:474936 CAPLUS Full-text

DOCUMENT NUMBER: 143:1315

TITLE: Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists

INVENTOR(S): Buntinx, Erik

PATENT ASSIGNEE(S): Belg.

SOURCE: U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 725,965.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20050119248	A1	20050602	US 2004-752423	20040106
<--				
US 7855195	B2	20101221		
US 20050119253	A1	20050602	US 2003-725965	20031202
<--				
US 7884096	B2	20110208		
US 20050119249	A1	20050602	US 2004-803793	20040318
<--				
US 20050203130	A1	20050915	US 2004-984683	20041109
<--				
CA 2547639	A1	20050616	CA 2004-2547639	20041202
<--				
WO 2005053796	A1	20050616	WO 2004-BE172	20041202
<--				

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

EP 1708790 A1 20061011 EP 2004-801138 20041202
 <--
 EP 1708790 B1 20100421
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
 BA, HR, IS, YU
 JP 2007513095 T 20070524 JP 2006-541759 20041202
 <--
 JP 4571645 B2 20101027
 AT 464901 T 20100515 AT 2004-801138 20041202
 <--
 PT 1708790 E 20100709 PT 2004-801138 20041202
 <--
 EP 2272514 A1 20110112 EP 2010-159625 20041202
 <--
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
 HR, LV, MK, YU
 US 20070078162 A1 20070405 US 2006-580962 20060531
 <--
 PRIORITY APPLN. INFO.: US 2003-725965 A2 20031202
 <--
 CA 2003-2451798 A 20031202
 <--
 EP 2003-447279 A 20031202
 <--
 EP 2004-447001 A 20040105
 US 2004-752423 A2 20040106
 CA 2004-2461248 A 20040318
 EP 2004-447066 A 20040318
 US 2004-803793 A2 20040318
 EP 2004-25035 A 20041021
 JP 2004-349085 A 20041104
 US 2004-984683 A 20041109
 CA 2004-2487529 A 20041115
 EP 2004-801138 A3 20041202
 WO 2004-BE172 W 20041202

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 INCL 514217000; 514220000; 514259410; 514469000; 514317000; 514649000
 IPCI A01N0043-46 [I,A]; A01N0043-26 [I,A]; A01N0033-02 [I,A]; A01N0033-24
 [I,A]; A61K0031-535 [I,A]; A61K0031-445 [I,A]; A61K0031-335 [I,A]
 IPCR A61K0031-00 [I,A]; A61K0031-343 [I,A]; A61K0031-445 [I,A]; A61K0031-4545
 [I,A]; A61K0031-519 [I,A]; A61K0031-55 [I,A]; A61K0031-551 [I,A];
 A01N0043-46 [I,A]; A01N0033-02 [I,A]; A01N0033-24 [I,A]; A01N0043-26
 [I,A]; A61K0031-335 [I,A]; A61K0031-535 [I,A]
 NCL 514/217.000; 514/220.000; 514/259.410; 514/317.000; 514/469.000;
 514/649.000; 514/232.800; 549/467.000
 CC 1-11 (Pharmacology)
 Section cross-reference(s): 63
 IT 5-HT reuptake inhibitors
 Antipsychotics

(as second compound; treating underlying dysregulation of emotional functionality of mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists)

IT 1841-19-6, FLUSPIRILENE 1893-33-0, PIPAMPERone 5786-21-0, CLOZAPINE 26615-21-4, ZOTEPINE 75558-90-6, AMPEROZIDE 85650-56-2, ORG 5222 87691-91-6, TIOspirone 106266-06-2, RISPERIDone 106516-24-9, SERTindole 127625-29-0, FANANSERIN 129029-23-8, OCAPERIDone 132539-06-1 139290-65-6 146939-27-7, ZIPRASIDone 158985-00-3, L 745870 169167-86-6, S16924 170858-34-1, PNU-101387G 200398-40-9, S18327

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (treating underlying dysregulation of emotional functionality of mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists)

E SSRI/IT

L9 656 S E51-E52,E53

L10 0 S L1 AND L9

L11 215 S SSRIS/IT

L12 0 S L1 AND L11

L13 7615 S ((SEROTONIN) (S) REUPTAKE (S) (INHIBIT?))

L14 12 S L1 AND L13

L15 5 S L14 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)

L16 1 S L15 NOT L8

E 5-HT ANTAGONISTS/IT

L17 3812 S 5-HT ANTAGONISTS/IT

L18 34 S L2 AND L17

L19 7 S L18 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)

L20 7 S L19 NOT (L8 OR L15)

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN

AB The present invention relates to the use of compds. and compns. of compds. having serotonin reuptake inhibiting activity and 5-HT2C antagonistic, partial agonistic or inverse agonistic activity for the for the treatment of depression and other affective disorders. The combined serotonin reuptake inhibiting effect and the 5-HT2C antagonistic, partial agonistic or inverse agonistic effect may reside within the same chemical compound or in two different chemical compds. E.g., simultaneous administration of 10 µmol/kg citalopram with 1 µmol/kg RS 102221 or Lu 27121 showed significant enhancement of the effect of citalopram in rats.

ACCESSION NUMBER: 2001:434808 CAPLUS Full-text

DOCUMENT NUMBER: 135:41033

TITLE: The combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist

INVENTOR(S): Cremers, Thomas Ivo Franciscus Hubert; Wikstroem, Hakan Wilhelm; Den Boer, Johan Antonie; Bosker, Fokko

Jan; Westerink, Bernard Hendrik Cornelis; Bogeso,

PATENT ASSIGNEE(S): Klaus Peter; Hogg, Sandra; Mork, Arne
 SOURCE: H. Lundbeck A/s, Den.
 PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001041701	A2	20010614	WO 2000-DK671	20001206
<--				
WO 2001041701	A3	20011213		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2393470	A1	20010614	CA 2000-2393470	20001206
<--				
AU 2001018511	A	20010618	AU 2001-18511	20001206
<--				
US 20020103249	A1	20020801	US 2000-731411	20001206
<--				
EP 1237553	A2	20020911	EP 2000-981174	20001206
<--				
EP 1237553	B1	20060104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
TR 2002001512	T2	20020923	TR 2002-1512	20001206
<--				
BR 2000016385	A	20030218	BR 2000-16385	20001206
<--				
HU 2002003586	A2	20030328	HU 2002-3586	20001206
<--				
HU 2002003586	A3	20050228		
JP 2003516326	T	20030513	JP 2001-542871	20001206
<--				
CN 1433313	A	20030730	CN 2000-818827	20001206
<--				
EP 1396267	A2	20040310	EP 2003-27672	20001206
<--				
EP 1396267	A3	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 314849	T	20060215	AT 2000-981174	20001206
<--				
PT 1237553	E	20060531	PT 2000-981174	20001206
<--				
ES 2255519	T3	20060701	ES 2000-981174	20001206
<--				
EP 1782813	A1	20070509	EP 2007-103057	20001206

<--	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI					
<--	IL 149994	A	20070724	IL 2000-149994	20001206	
<--	NZ 545907	A	20070727	NZ 2000-545907	20001206	
<--	EP 2036564	A1	20090318	EP 2008-21043	20001206	
<--	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI					
<--	CN 101406465	A	20090415	CN 2008-10149947	20001206	
<--	ZA 2002004391	A	20030901	ZA 2002-4391	20020531	
<--	NO 2002002657	A	20020726	NO 2002-2657	20020605	
<--	MX 2002005613	A	20021213	MX 2002-5613	20020606	
<--	US 20030032636	A1	20030213	US 2002-165196	20020606	
<--	KR 832026	B1	20080523	KR 2002-7007231	20020607	
<--	HR 2002000527	A2	20041231	HR 2002-527	20020617	
<--	BG 106895	A	20030430	BG 2002-106895	20020702	
<--	IN 213140	A1	20080331	IN 2002-CN1026	20020703	
<--	AU 2006200878	A1	20060323	AU 2006-200878	20060301	
<--	US 20070105843	A1	20070510	US 2006-539100	20061005	
<--	US 20090176808	A1	20090709	US 2009-406226	20090318	
<--	AU 2009202463	A1	20090709	AU 2009-202463	20090619	
<--	PRIORITY APPLN. INFO.:			US 1999-169245P	P	19991206
<--				AU 2001-18511	A3	20001206
<--				CN 2000-818827	A3	20001206
<--				EP 2000-981174	A3	20001206
<--				EP 2003-27672	A3	20001206
<--				EP 2007-103057	A3	20001206
<--				US 2000-731411	B1	20001206
<--				WO 2000-DK671	W	20001206
<--				US 2002-165196	B1	20020606
<--				AU 2006-200878	A3	20060301
<--				US 2006-539100	A3	20061005

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

IPCI A61K [ICM,7]

IPCR A61K [I,S]; A61K0031-00 [I,A]; A61K0031-135 [I,A]; A61K0031-137 [I,A];
A61K0031-138 [I,A]; A61K0031-15 [I,A]; A61K0031-343 [I,A]; A61K0031-405
[I,A]; A61K0031-4439 [I,A]; A61K0031-445 [I,A]; A61K0031-4525 [I,A];
A61K0031-496 [I,A]; A61K0031-513 [I,A]; A61K0031-519 [I,A]; A61K0031-55
[I,A]; A61K0031-551 [I,A]; A61K0033-36 [I,A]; A61K0045-06 [I,A];
A61P0001-14 [I,A]; A61P0003-04 [I,A]; A61P0025-20 [I,A]; A61P0025-22
[I,A]; A61P0025-24 [I,A]; A61P0025-28 [I,A]; A61P0025-30 [I,A];
A61P0043-00 [I,A]; G01N0033-94 [I,A]

CC 1-11 (Pharmacology)

Section cross-reference(s): 63

IT 5-HT antagonists

(5-HT2C; combination of a serotonin reuptake inhibitor and a 5-HT2C
antagonist, inverse agonist or partial agonist)

IT 50-49-7, Imipramine 303-49-1, Clomipramine 24219-97-4, Mianserine
54739-18-3, Fluvoxamine 59859-58-4, Femoxetine 61869-08-7,

Paroxetine

79617-96-2, Sertraline 83366-66-9, Nefazodone 85650-52-8,

Mirtazapine

87051-43-2, Ritanserin 93413-69-5, Venlafaxine 106516-24-9,

Sertindole

119356-77-3, Dapoxetine 120444-71-5, Deramciclane 128196-01-0

, Escitalopram 158942-04-2, SB 206553 161178-10-5, YM 35992

181632-25-7, SB 242084 200940-22-3, SB 243213 210821-63-9, Org 12962

344454-50-8, SB 228356 344454-51-9, Ro 60-0795 344454-52-0, Org

38457

344454-70-2, EGIS 8465

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination of a serotonin reuptake inhibitor and a 5-HT2C
antagonist,

inverse agonist or partial agonist)

L21 211 S (5-HT-2A?)

L22 0 S L2 AND L21

L23 5563 S (5-HT2A?)

L24 35 S L2 AND L23

L25 8 S L24 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)


L26 4 S L25 NOT (L8 OR L15 OR L19)

FILE 'CAPLUS' ENTERED AT 10:55:12 ON 11 JUL 2011

L27 1 S US 20070248697/PN

E PIPAMPERONE/CN

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2011 ACS on STN
RN 1893-33-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[4-(4-fluorophenyl)-4-oxobutyl]-
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[3-(p-fluorobenzoyl)propyl]-
(7CI,
8CI)
OTHER NAMES:
CN 1'-[3-(p-Fluorobenzoyl)propyl][1,4'-bipiperidine]-4'-carboxamide
CN 1-(p-Fluorophenyl)-4-(4-piperidino-4-carbamoylpiperidino)-1-butanone
CN 4'-Fluoro-4-[4-N-piperidino-4-carbamidopiperidino]butyrophenone
CN 4'-Fluoro-4-{N-[4-(N-piperidino)-4-carbamido]piperidino}butyrophenone
CN Dipiperal
CN Dipiperon
CN Dipiperone
CN Floropipamide
CN McN-JR 3345
CN Pipamperone
CN R 3345
MF C21 H30 F N3 O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS,
BIOTECHNO,
CA, CAPLUS, CHEMCATS, CHEMLIST, DDFU, DRUGU, EMBASE, IPA, MEDLINE,
MRCK*, PS, REAXYSFILE*, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2,
USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: WHO



```

SET EXPAND CONTINUOUS
L1          1 S E3

FILE 'CAPLUS' ENTERED AT 15:36:21 ON 20 JUL 2011
L2          7 S US 20070078162/PN
L3          329 S L1
             E ANXIETY/CT
L4          64940 S E15+ALL/CT
             E E15+ALL/CT
L5          17114 S E29,E34
             E ANXIOLYTICS/CT
             E E38+ALL/CT
L6          12946 S E53,E59
             E EMOTION/CT
             E E63+ALL/CT
L7          148471 S E76,E80-E84
             E MENTAL AND BEHAVIORAL DISORDERS/CT
             E E87+ALL/CT
L8          258158 S E101-E105,E132-E195,E197
             E ANTIPSYCHOTICS/CT
             E E202+ALL/CT
L9          297254 S E229,E142-E242,E244-E245
             E PSYCHOTROPICS/CT
             E E255+ALL/CT
L10         77681 S E270-E273,E280,E291,E313,E321,E327-E328,E334
L11         217 S L3 AND (L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR L10)
L12         145 S L11 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)
L13         0 S L3 (L) (L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR L10)

```